Chief Scientific Officer

Dr. Tracy McGowan recently retired after nearly 20 years at Johnson & Johnson (J&J), where she most recently served as the Therapeutic Area Head for Prostate Cancer. During her tenure, she led cross-functional teams responsible for the successful launch of nine new oncology therapies—three for prostate cancer and one for bladder cancer. Her leadership was instrumental in designing pivotal clinical trials, fostering collaborations with leading scientific and advocacy organizations, and building high-performing teams that earned widespread recognition through publications and presentations.

Before joining J&J, Dr. McGowan was an Associate Professor in the Divisions of Clinical Pharmacology and Nephrology at Thomas Jefferson University School of Medicine and Hospital, where she contributed to academic research and medical education.

Dr. McGowan brings a wealth of industry and academic experience to the PCEC, with a particular focus on addressing health disparities in underserved communities. Her deep understanding of barriers to cancer screening and access to clinical trials enhances the diverse expertise of the current board.

Prostate cancer is a disease that is most successfully treated when it is detected early on.  As the research community explores various methods to detecting the disease, PCEC continues to encourage men to play an active role in their health by looking to those trusted sources of prostate cancer testing – the PSA and DRE.

Join Our Newsletter